These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26681486)

  • 41. Mucosal Healing in Ulcerative Colitis--When Zero is Better.
    Boal Carvalho P; Dias de Castro F; Rosa B; Moreira MJ; Cotter J
    J Crohns Colitis; 2016 Jan; 10(1):20-5. PubMed ID: 26438714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.
    Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
    J Crohns Colitis; 2015 Jan; 9(1):56-65. PubMed ID: 25518051
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repeated intensified infliximab induction - results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm.
    Johnsen KM; Goll R; Hansen V; Olsen T; Rismo R; Heitmann R; Gundersen MD; Kvamme JM; Paulssen EJ; Kileng H; Johnsen K; Florholmen J
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):98-104. PubMed ID: 27749779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
    Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
    Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
    Telesco SE; Brodmerkel C; Zhang H; Kim LL; Johanns J; Mazumder A; Li K; Baribaud F; Curran M; Strauss R; Paxson B; Plevy S; Davison T; Knight L; Dibben S; Schreiber S; Sandborn W; Rutgeerts P; Siegel CA; Reinisch W; Greenbaum LE
    Gastroenterology; 2018 Oct; 155(4):1008-1011.e8. PubMed ID: 29981298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
    Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
    J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Baert F; Vande Casteele N; Tops S; Noman M; Van Assche G; Rutgeerts P; Gils A; Vermeire S; Ferrante M
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1324-32. PubMed ID: 25277873
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
    Viazis N; Giakoumis M; Bamias G; Goukos D; Koukouratos T; Katopodi K; Karatzas P; Triantos C; Tsolias C; Theocharis G; Daikos GL; Ladas SD; Karamanolis DG; Mantzaris GJ
    Dig Liver Dis; 2017 Jan; 49(1):29-33. PubMed ID: 27866814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study.
    Prieux-Klotz C; Nahon S; Amiot A; Sinayoko L; Galéano-Cassaz C; Chaussade S; Coriat R; Lahmek P; Abitbol V
    Dig Dis Sci; 2017 Feb; 62(2):473-480. PubMed ID: 27853898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.
    Nakarai A; Kato J; Hiraoka S; Inokuchi T; Takei D; Moritou Y; Akita M; Takahashi S; Hori K; Harada K; Okada H; Yamamoto K
    World J Gastroenterol; 2014 Dec; 20(48):18367-74. PubMed ID: 25561804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
    De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
    J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.
    Dai C; Liu WX; Jiang M; Sun MJ
    PLoS One; 2014; 9(10):e110797. PubMed ID: 25330148
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission.
    Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Sociale O; Papa A; De Vitis I; Rapaccini GL; Guidi L
    Inflamm Bowel Dis; 2013 Apr; 19(5):1065-72. PubMed ID: 23448790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
    Patel A; Panchal H; Dubinsky MC
    Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.